Back

Bayer initiates Phase II study of investigational GIRK4 inhibitor in atrial fibrillation

Verifying
  • Bayer initiated a Phase II study of an investigational GIRK4 inhibitor.
  • The study involves patients with atrial fibrillation.
  • The program is at the Phase II clinical-development stage.
The information on this website is generated using AI and we cannot guarantee its accuracy. Please use it as reference information only.